New Lifetime High Today: Pacira Pharmaceuticals (PCRX)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Pacira Pharmaceuticals ( PCRX) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Pacira Pharmaceuticals as such a stock due to the following factors:

  • PCRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $50.5 million.
  • PCRX has traded 5,031 shares today.
  • PCRX is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PCRX with the Ticky from Trade-Ideas. See the FREE profile for PCRX NOW at Trade-Ideas

More details on PCRX:

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. Currently there are 6 analysts that rate Pacira Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Pacira Pharmaceuticals has been 456,100 shares per day over the past 30 days. Pacira has a market cap of $3.5 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.11 and a short float of 20.6% with 7.91 days to cover. Shares are up 73.2% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Pacira Pharmaceuticals Tops 4Q Earnings Expectations

Biotech Premarket Movers: Pacira, Clearside Biomedical and Organovo

Bullish and Bearish Reversals in the Market

Analysts' Actions -- Quintiles, Royal Caribbean, Western Digital and More